StockData
Amgen Inc logo

Amgen Inc

AMGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 17/3039% above fair value
$465.45−0.56 (-0.12%)

Close on Nov 2, 2026Market cap $251.64BP/E 28.9Yield 2.08%

Amgen Nplate (romiplostim by Quarter

Nplate (romiplostim — Immune Thrombocytopenia) — Worldwide volume growth YoY (%) (%)

QuarterlyAnnual

Amgen Nplate (romiplostim: 13.0% in Q2 2026.

Latest, Q2 2026
13.0%
Period ended Jun 30, 2026
Change on a year earlier
–
History
13 quarters
Since Q1 2021
Sources
13
Documents cited below

Where the Q2 2026 figure comes from

“Nplate ® (romiplostim) sales increased 17% year-over-year to $430 million in the second quarter, driven by 13% volume growth and higher net selling price.”

Source: Form 8-K (amgn-20260630earningsrelea.htm, filed 2026-08-04) ↗

Reported in Form 8-K Product Sales Performance & Form 10-Q / 10-K MD&A.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedNplate (romiplostim — Immune Thrombocytopenia) — Worldwide volume growth YoY (%) (%)Year on yearSource
Q2 2026Jun 30, 202613.0%–Form 8-K (amgn-20260630earningsrelea.htm, filed 2026-08-04) ↗
Q1 2026Mar 31, 20268.0%–Form 8-K (amgn-20260331earningsrelea.htm, filed 2026-04-30) ↗
Q4 2025Dec 31, 20259.0%–Form 8-K (amgn-20251231earningsrelea.htm, filed 2026-02-03) ↗
Q3 2024Sep 30, 202414.0%-29.0 ptsForm 8-K (amgn-20240930earningsrelea.htm, filed 2024-10-30) ↗
Q3 2023Sep 30, 202343.0%+31.0 ptsForm 8-K (amgn-2023930earningsrelease.htm, filed 2023-10-31) ↗
Q2 2023Jun 30, 202315.0%+4.0 ptsForm 8-K (amgn-2023630earningsrelease.htm, filed 2023-08-03) ↗
Q1 2023Mar 31, 202341.0%+34.0 ptsForm 8-K (amgn-2023331earningsrelease.htm, filed 2023-04-27) ↗
Q3 2022Sep 30, 202212.0%-2.0 ptsForm 8-K (amgn-2022930earningsrelease.htm, filed 2022-11-03) ↗
Q2 2022Jun 30, 202211.0%-6.0 ptsForm 8-K (amgn-2022630earningsrelease.htm, filed 2022-08-04) ↗
Q1 2022Mar 31, 20227.0%-16.0 ptsForm 8-K (amgenq12022earningsrelease.htm, filed 2022-04-27) ↗
Q3 2021Sep 30, 202114.0%–Form 8-K (amgn-2021930xq3ex991.htm, filed 2021-11-02) ↗
Q2 2021Jun 30, 202117.0%–Form 8-K (amgn-2021630xq2ex991.htm, filed 2021-08-03) ↗
Q1 2021Mar 31, 202123.0%–Form 8-K (amgn-2021331xq1ex991.htm, filed 2021-04-27) ↗

Cite this data

StockData. (2026). Amgen Nplate (romiplostim (%), quarterly Q1 2021–Q2 2026 [Data set]. Compiled from Amgen SEC filings and investor materials. https://stockdatahq.com/stocks/amgn/kpis/prod-nplate-vol

See every metric in the Amgen KPI table. Data updated Oct 28, 2026.